Open Access

Dihydroartemisinin inhibits endothelial cell migration via the TGF‑β1/ALK5/SMAD2 signaling pathway

  • Authors:
    • Ling Guo
    • Xiaoqing Wen
    • Yinglong Hou
    • Rong Sun
    • Liang Zhang
    • Fuhong Liu
    • Ju Liu
  • View Affiliations

  • Published online on: May 3, 2021     https://doi.org/10.3892/etm.2021.10141
  • Article Number: 709
  • Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Anti‑angiogenesis therapy is a novel treatment method for malignant tumors. Endothelial cell (EC) migration is an important part of angiogenesis. Dihydroartemisinin (DHA) exhibits strong anti‑angiogenic and anti‑EC migration effects; however, the underlying molecular mechanisms are yet to be elucidated. The TGF‑β1/activin receptor‑like kinase 5 (ALK5)/SMAD2 signaling pathway serves an important role in the regulation of migration. The present study aimed to explore the effects of DHA treatment on EC migration and the TGF‑β1/ALK5/SMAD2 signaling pathway. The effects of DHA on human umbilical vein EC migration were assessed using wound healing and Transwell assays. The effects of DHA on the TGF‑β1/ALK5/SMAD2 signaling pathway were detected using western blotting. DHA exhibited an inhibitory effect on EC migration in the wound healing and Transwell assays. DHA treatment upregulated the expression levels of ALK5 and increased the phosphorylation of SMAD2 in ECs. SB431542 rescued the inhibitory effect of DHA during EC migration. DHA inhibited EC migration via the TGF‑β1/ALK5/SMAD2‑dependent signaling pathway, and DHA may be a novel drug for the treatment of patients with malignant tumors.

Related Articles

Journal Cover

July-2021
Volume 22 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Guo L, Wen X, Hou Y, Sun R, Zhang L, Liu F and Liu J: Dihydroartemisinin inhibits endothelial cell migration via the TGF‑β1/ALK5/SMAD2 signaling pathway. Exp Ther Med 22: 709, 2021
APA
Guo, L., Wen, X., Hou, Y., Sun, R., Zhang, L., Liu, F., & Liu, J. (2021). Dihydroartemisinin inhibits endothelial cell migration via the TGF‑β1/ALK5/SMAD2 signaling pathway. Experimental and Therapeutic Medicine, 22, 709. https://doi.org/10.3892/etm.2021.10141
MLA
Guo, L., Wen, X., Hou, Y., Sun, R., Zhang, L., Liu, F., Liu, J."Dihydroartemisinin inhibits endothelial cell migration via the TGF‑β1/ALK5/SMAD2 signaling pathway". Experimental and Therapeutic Medicine 22.1 (2021): 709.
Chicago
Guo, L., Wen, X., Hou, Y., Sun, R., Zhang, L., Liu, F., Liu, J."Dihydroartemisinin inhibits endothelial cell migration via the TGF‑β1/ALK5/SMAD2 signaling pathway". Experimental and Therapeutic Medicine 22, no. 1 (2021): 709. https://doi.org/10.3892/etm.2021.10141